Crossmark

Implicating or exonerating the gut microbiome in blood-borne infection

Crossref DOI link: https://doi.org/10.1038/s41591-018-0270-9

Published Online: 2018-12-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gopalakrishnan, Vancheswaran

Jenq, Robert R.
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

First Online: 3 December 2018

Competing Interests

: V.G. is an inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. V.G. reports honoraria from EXCEL CME and Kansas Society of Clinical Oncology and consultancy fees from MicrobiomeDX and ExpertConnect. R.R.J. is on the scientific advisory board for Seres Therapeutics, Inc., has consulted for Ziopharm Oncology, MicrobiomeDx and Merck, and holds patents licensed to Seres Therapeutics, Inc.